Craig A. Wheeler Sells 10,406 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 10,406 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $15.89, for a total value of $165,351.34. Following the completion of the transaction, the chief executive officer now owns 275,526 shares in the company, valued at approximately $4,378,108.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Craig A. Wheeler also recently made the following trade(s):
- On Tuesday, November 21st, Craig A. Wheeler sold 4,116 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $13.35, for a total value of $54,948.60.
Shares of Momenta Pharmaceuticals, Inc. (MNTA) opened at $16.30 on Tuesday. The stock has a market capitalization of $1,250.00, a price-to-earnings ratio of -20.38 and a beta of 1.80. Momenta Pharmaceuticals, Inc. has a 12-month low of $11.85 and a 12-month high of $19.55.
MNTA has been the topic of several research analyst reports. Zacks Investment Research upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. BidaskClub downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Cowen set a $15.00 target price on Momenta Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, November 1st. Finally, Stifel Nicolaus restated a “hold” rating and set a $18.00 target price on shares of Momenta Pharmaceuticals in a research report on Tuesday, January 30th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company’s stock. Momenta Pharmaceuticals currently has an average rating of “Hold” and an average price target of $15.30.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.